Generic Medicine Info
Sepsis or risk of sepsis; active infections including chronic or localised infections.
Special Precautions
Patient w/ history of recurring or chronic infections or w/ underlying conditions that may predispose patient to infections (e.g. advanced or poorly controlled DM); previous hepatitis B virus infection; history of hepatitis C, blood dyscrasias; pre-existing or recent onset of demyelinating disease; CHF, moderate to severe alcoholic hepatitis. Childn. Pregnancy and lactation. Monitoring Parameters Monitor CBC w/ differential; signs/symptoms of infection (prior to, during and after therapy), heart failure, hypersensitivity reactions, lupus-like syndrome, malignancy. Perform screening for latent TB (prior to and during therapy), hepatitis B virus (HBV); HBV carriers.
Adverse Reactions
Nausea, vomiting, dyspepsia, headache, dizziness, asthenia, allergic reactions, development of autoantibodies, fever; mild to moderate inj site reactions (e.g. erythema, itching, pain, swelling).
Potentially Fatal: Serious infections and sepsis (e.g. TB, invasive fungal infections), malignancies (e.g. breast, lung and skin cancers; lymphoma). Rarely, pancytopenia, aplastic anaemia, central and peripheral demyelinating events, lupus, lupus-related conditions and vasculitis; anaphylaxis.
Drug Interactions
Decreased WBC w/ sulfasalazine. Increased risk of serious infections and neutropenia w/ anakinra. Increased incidence of serious adverse events w/ abatacept. Higher incidence of non-cutaneous solid malignancies w/ cyclophosphamide. May diminish the therapeutic effect of live vaccines.
ATC Classification
L04AB01 - etanercept ; Belongs to the class of tumor necrosis factor alpha (TNF-a) inhibitors. Used as immunosuppressants.
Disclaimer: This information is independently developed by CIMS based on etanercept from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in